Chemotherapy of multiple myeloma: Melphalan—40 years old and still going strong-Reference-Cited by-同舟云学术

Chemotherapy of multiple myeloma: Melphalan—40 years old and still going strong

Published:2003-01 Issue:1 Volume:9 Page:2-3
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Bergsagel P.Leif

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference11 articles.

1. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard (NSC-8806);Bergsagel;Cancer Chemother Rep,1962

2. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials;Gregory;J Clin Oncol,1992

3. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review;Hahn;Biol Blood Marrow Transplant,2003

4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;N Engl J Med,1996

5. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group;Lenhoff;Blood,2000

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nano-sized melphalan and sarcolysine drug delivery systems: synthesis and prospects of application;Russian Chemical Reviews;2013-08-31

2. WOMEN?S MOVEMENTS AND NEW PUBLIC MANAGEMENT: HIGHER EDUCATION IN SWEDEN AND ENGLAND;Public Administration;2007-03

3. An update: Health economics of managing multiple myeloma;European Journal of Cancer;2006-07

4. First results of a quantitative study of DNA adducts of melphalan in the rat by isotope dilution mass spectrometry using capillary liquid chromatography coupled to electrospray tandem mass spectrometry;Rapid Communications in Mass Spectrometry;2005

5. Activity of single-agent melphalan 220–300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma;Bone Marrow Transplantation;2004-02-09